Drug
D0374 | Niclosamide
P
P02DA01 Niclosamide
[P02DA] Salicylic acid derivatives
[P02D] ANTICESTODALS
[P02] ANTHELMINTICS
[P] Antiparasitic products, insecticides and repellents
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 0.03±0.01 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 0.1 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 0.44±0.27 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| GLUCOSE GALACTOSE IC50 RATIO | 1.4 | LUHMES (Lund human mesencephalic) cells | Glc–Gal–NeuriTox assay | Negative | EC25(NA) [Glc/Gal] | 326 | ||
| FRAGMENTATION | 1, 5, and 10 uM | 3 hr (1.5-6hr) | HeLa/mito-YFP | fluorescence microscope | induce | 294 | ||
| APOPTOSIS | induce | 294 | ||||||
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Warning |
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H400 (100%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard] H410 (100%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard] |
P264, P273, P280, P305+P351+P338, P337+P313, P391, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
|
|
Warning |
Aggregated GHS information provided by 70 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H400 (97.14%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard] H410 (38.57%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P273, P391, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | intravenous | 7500ug/kg (7.5mg/kg) | behavioral: convulsions or effect on seizure threshold | Arzneimittel-Forschung. Drug Research. Vol. 10, Pg. 884, 1960. |
| rat | LD50 | intraperitoneal | 250mg/kg (250mg/kg) | Zeitschrift fuer Tropenmedizin und Parasitologie. Vol. 13, Pg. 1, 1962. | |
| cat | LD | oral | > 1gm/kg (1000mg/kg) | French Medicament Patent Document. Vol. #2628M, | |
| rabbit | LD | oral | > 5gm/kg (5000mg/kg) | French Medicament Patent Document. Vol. #2628M, | |
| mouse | LD50 | oral | 1gm/kg (1000mg/kg) | "Wirksubstanzen der Pflanzenschutz und Schadlingsbekampfungsmittel," Perkow, W., Berlin, Verlag Paul Parey, 1971-1976Vol. -, Pg. -, 1971/1976. | |
| rat | LD50 | oral | 2500mg/kg (2500mg/kg) | "Agrochemicals Handbook," with updates, Hartley, D., and H. Kidd, eds., Nottingham, Royal Soc of Chemistry, 1983-86Vol. A297, Pg. 1983, | |
| (5-chloro-2-hydroxyphenyl)-N-(2-chloro-4-nitrophenyl)carboxamide | 2 inverted exclamation marka,5-Dichloro-4 inverted exclamation marka-nitrosalicylanilide | 2',5'-Dichloro-4'-nitrosalicylanilide |
| 2',5-Dichlor-4'-nitro-salizylsaeureanilid | 2',5-Dichlor-4'-nitro-salizylsaeureanilid [German] | 2',5-Dichloro-4'-nitrosalicylanilide |
| 2,5-dichloro-4-nitrosalicylanilide ? | 2-Chloro-4-nitrophenylamide-6-chlorosalicylic acid | 2-Hydroxy-5-chloro-N-(2-chloro-4-nitrophenyl)benzamide |
| 5-CHLORO-N-(2-CHLORO-4-NITROPHENYL)-SALICYLAMIDE/N | 5-Chloro-2'-chloro-4'-nitrosalicylanilide | 5-Chloro-N-(2'-chloro-4'-nitrophenyl)salicylamide |
| 5-Chloro-N-(2-chloro-4-nitro-phenyl)-2-hydroxy-benzamide | 5-Chloro-N-(2-chloro-4-nitrophenyl) -2-hydroxybenzamide | 5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide |
| 5-Chlorosalicyloyl-(o-chloro-p-nitranilide) | 5-chloranyl-N-(2-chloranyl-4-nitro-phenyl)-2-oxidanyl-benzamide | 5-chloro-N-(2-chloro-4-nitrophenyl)- |
| 50-65-7 | 8KK8CQ2K8G | A828227 |
| AB00052340 | AB00052340_08 | AB00052340_09 |
| AB0013423 | AB1011456 | AI3-25823 |
| AK173020 | AKOS003589004 | Atenase |
| B 2353 | BAY 2353 | BAY-2353 |
| BAY2353 | BBL004110 | BCP22958 |
| BCP9000068 | BDBM11242 | BPBio1_000153 |
| BRD-K35960502-001-06-9 | BRD-K35960502-001-11-9 | BRN 2820605 |
| BSPBio_000139 | BSPBio_002333 | Bayer 2353 |
| Bayer 73 | Bayluscid | Benzamide, 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy- |
| C13H8Cl2N2O4 | CAS-50-65-7 | CCG-39641 |
| CCRIS 3437 | CHEBI:7553 | CHEMBL1448 |
| CS-2618 | CTK8G1852 | Cestocid |
| Cestocide | Chemagro 2353 | Clonitralid (Salt/Mix) |
| Clonitralide (Salt/Mix) | D00436 | DB-051812 |
| DB06803 | DSSTox_CID_20362 | DSSTox_GSID_40362 |
| DSSTox_RID_79485 | DTXSID7040362 | Devermin |
| Devermine | Dichlosale | DivK1c_000709 |
| EINECS 200-056-8 | EN300-92958 | ENT 25823 |
| EU-0100866 | FT-0603220 | Fedal-Telmin |
| Fenasal | GTPL8494 | HL 2447 |
| HMS1568G21 | HMS2093A21 | HMS2095G21 |
| HMS2231H06 | HMS3262N13 | HMS3373P08 |
| HMS3712G21 | HMS502D11 | HSDB 1572 |
| HY-B0497 | Helmiantin | I012 |
| IDI1_000709 | Iomesan | Iomezan |
| KBio1_000709 | KBio2_000719 | KBio2_003287 |
| KBio2_005855 | KBio3_001553 | KBioGR_000771 |
| KBioSS_000719 | KS-00000JFD | KS-5210 |
| KSC-18-157-2 | KUC107299N | LP00866 |
| LS-144196 | Lintex | Lopac-N-3510 |
| Lopac0_000866 | MCULE-9985514311 | MFCD00057597 |
| MLS002154181 | Mansonil | Mato |
| Mollutox (Salt/Mix) | N 3510 | N-(2'-Chlor-4'-nitrophenyl)-5-chlorsalicylamid |
| N-(2'-Chlor-4'-nitrophenyl)-5-chlorsalicylamid [German] | N-(2'-Chloro-4'-nitrophenyl)-5-chlorosalicylamide | N-(2-Chloro-4-nitrophenyl)-5-chlorosalicylamide |
| NCGC00015735-01 | NCGC00015735-02 | NCGC00015735-03 |
| NCGC00015735-04 | NCGC00015735-05 | NCGC00015735-06 |
| NCGC00015735-07 | NCGC00015735-08 | NCGC00015735-09 |
| NCGC00015735-11 | NCGC00015735-12 | NCGC00094190-01 |
| NCGC00094190-02 | NCGC00094190-03 | NCGC00094190-04 |
| NCGC00254654-01 | NCGC00261551-01 | NINDS_000709 |
| NSC 178296 | NSC-178296 | NSC-758440 |
| NSC178296 | NSC758440 | Nasemo |
| Niclocide | Niclocide (TN) | Niclosamida |
| Niclosamida [INN-Spanish] | Niclosamide (Niclocide) | Niclosamide (USAN/INN) |
| Niclosamide (anhydrous), European Pharmacopoeia (EP) Reference Standard | Niclosamide Anhydrous | Niclosamide [BSI:ISO] |
| Niclosamide [USAN:INN:BAN] | Niclosamide, 97+% | Niclosamidum |
| Niclosamidum [INN-Latin] | Nitrophenyl chlorsalicylamide | Oprea1_259151 |
| Pharmakon1600-01503265 | Phenasal | Prestwick0_000040 |
| Prestwick1_000040 | Prestwick2_000040 | Prestwick3_000040 |
| Prestwick_354 | Q-201469 | Q418523 |
| RJMUSRYZPJIFPJ-UHFFFAOYSA-N | Radeverm | Radewerm |
| Ruby | SB19414 | SBI-0050841.P003 |
| SC-46581 | SCHEMBL18563900 | SCHEMBL67182 |
| SMP2_000228 | SMR000058390 | SPBio_001225 |
| SPBio_002060 | SPECTRUM1503265 | SR 73 |
| SR-01000076024 | SR-01000076024-1 | SR-01000076024-3 |
| SR-01000076024-6 | ST50408862 | STK396676 |
| Sagimid | Salicylanilide, 2',5-dichloro-4'-nitro- | Salicylanilide,5-dichloro-4'-nitro- |
| Spectrum2_001183 | Spectrum3_000667 | Spectrum4_000196 |
| Spectrum5_001083 | Spectrum_000239 | Sulqui |
| T7903 | Tox21_110209 | Tox21_110209_1 |
| Tox21_300749 | Tox21_500866 | Tredemine |
| UNII-8KK8CQ2K8G | VU0243604 | Vermitid |
| WLN: WNR CG DMVR BQ EG | WR 46234 | Yomensan |
| Yomesan | Z57902203 | ZINC3874496 |
| Zestocarp | niclosamide | niclosamide-niclocide |
| nicolsamide | s3030 |
| DrugBank Name | Niclosamide |
| DrugBank | DB06803 |
| CAS Number | 1420-04-8, 50-65-7, 81424-66-0 |
| PubChem Compound | 4477 |
| KEGG Drug | D00436 |
| PubChem.Substance | 99443295 |
| ChEBI | 7553 |
| PharmGKB | PA165958408 |
| ChemSpider | 4322 |
| BindingDB | 11242.0 |
| Wikipedia | Niclosamide |